Implications of SARS-CoV-2 genetic diversity and mutations on pathogenicity of the COVID-19 and biomedical interventions

Idris N. Abdullahi, MSc, Anthony U. Emeribe, MSc, Onaoluwa A. Ajayi, MSc, Bamidele S. Oderinde, PhD, Dele O. Amadu, MSc and Ahaneku I. Osuji, PhD

Department of Medical Laboratory Science, Faculty of Allied Health Sciences, Ahmadu Bello University, Zaria, Nigeria

Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, University of Calabar, Calabar, Nigeria

Department of Medical Laboratory Services, Ogun State Hospital Management Board, Abeokuta, Nigeria

Department of Medical Laboratory Science, Faculty of Allied Health Sciences, College of Medical Sciences, University of Maiduguri, Maiduguri, Nigeria

Department of Medical Microbiology and Parasitology, University of Ilorin Teaching Hospital, Ilorin, Nigeria

Department of Medical Laboratory Services, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria

Received 9 April 2020; revised 2 June 2020; accepted 6 June 2020; Available online 10 July 2020

Abstract

Objective: Coronavirus disease 2019 (COVID-19) has caused an unprecedented global health emergency. The COVID-19 pandemic has claimed over 350,000 human lives within five months of its emergence, especially in the USA and the European continent. This study analysed the implications of the genetic diversity and mutations in SARS-CoV-2 on its virulence diversity and investigated how these factors could affect the successful development and application of antiviral chemotherapy and serodiagnostic test kits, and vaccination.

Methods: All the suitable and eligible full text articles published between 31st December 2019 and 31st May 2020 were filtered and extracted from “PubMed”, “Scopus”, “Web of Science”, and “Hinari” and were critically reviewed.

Keywords: Coronavirus disease 2019 (COVID-19), SARS-CoV-2, Mutations, Genetic diversity, Virulence diversity, Antiviral chemotherapy, Serodiagnostic test kits, Vaccination.
Introduction

The incidence of coronavirus disease 19 (COVID-19) continues to rise globally. In addition, the case fatality rate (CFR) of COVID-19 has appeared to be disproportionate among countries across the world. As on 29th May 2020, 9:00 AM GMT+1, there were 5,920,086 confirmed cases of COVID-19 globally with CFR of 6.1%.  

Majority of people infected with SARS-CoV-2 remain asymptomatic and infection being self-limiting. However, approximately 2% of infected persons suffer from severe form of COVID-19.  

Results and discussion

SARS-CoV-2 is single-stranded RNA virus with positive polarity and variable open reading frames (ORFs). It has been shown that two-third of the SARS-CoV-2 genome is located within the 1st ORF, which translates the pp1a and pp1ab polyproteins. These polyproteins encode 16 non-structural proteins (NSPs). Conversely, the remaining ORFs code for the structural and accessory proteins of SARS-CoV-2. The remaining one-third of the genome codes for the nucleocapsid (N) protein, spike (S) glycoprotein, matrix (M) protein, and small envelope (E) protein. Out of the four structural proteins, the S protein plays the most important role in host cell attachment and entry. It is also the target for development of antibodies, antivirals, and vaccines. The S protein primarily mediates invasion of the host cell by binding to a receptor called angiotensin-converting enzyme 2 (ACE2). The S protein is cleaved into an N-terminal S1 subunit and a membrane bound C-terminal S2 region by the host proteases.  

Destabilisation of the pre-fusion trimer could occur during the binding of the S1 subunit to the host receptor, which could lead to shedding of the S1 subunit and formation of a highly stable post-fusion conformation by the transitioned S2 subunit. Essentially, the receptor binding domain (RBD) of the S1 unit could undergo a hinge-like conformational
Physiologically, the ACE2 receptors are expressed in the nasal epithelial, lung, spermatogonial, Leydig, Sertoli, gastric, duodenal, and rectal epithelial cells. It has been reported that the RBD on the S protein is the most variable genomic component of SARS-CoVs and some sites of this protein might be subjected to positive selection. Despite the significantly high variability of SARS-CoV-2, one key phenomenon that needs thorough investigation is how S protein mutations affect the functional pathogenicity of SARS-CoV-2.

An important and common feature of viruses is their increased transmissibility usually accompanied by decreased virulence, which can also be observed for SARS-CoV-2. Indeed, this has reflected in the COVID-19 trajectory, as this could be an explanation for the high COVID-19 incidence rate reported by the hard-hit countries (Table 1). For instance, COVID-19 was more severe in Wuhan in the early stage of the pandemic with 32% severe cases and 11% case fatality. However, later data from Wuhan showed more mild form of SARS-CoV-2 infection compared to Zhejiang and the entire China. The transmissibility of SARS-CoV-2 increased from varied reproductive number (R0) of 2.212—2.686 in Wuhan to R0 of 3.7713 in the entire China. In addition, this observation was similar to SARS-CoV-2 viral load of symptomatic and asymptomatic COVID-19 patient which revealed the capacity of occult SARS-CoV-2 transmission. Indeed, these observations in the clinic-epidemiological features of COVID-19 were related to mutations in S protein of SARS-CoV-2.

Available genomic surveillance data of SARS-CoV-2 suggest presence of abundant single nucleotide variants. For instance, in a recent study, Yao et al. reported a direct link between genomic mutations and variation in the pathogenicity of SARS-CoV-2. The study characterised SARS-CoV-2 isolates from 11 patients. From these, six different mutations in the S protein were detected. Out of the six mutations, two were different Single Nucleotide Variants (SNVs) that led to similar missense mutation. Importantly, the SARS-CoV-2 isolates showed significantly varied cytopathic effects (CPEs) and viral loads in Vero-E6 cells, indicating that SARS-CoV-2 mutations are capable of causing substantial changes in the pathogenicity of the virus.

In early May 2020, two new studies on deep RNA sequencing of SARS-CoV-2 conducted in search for...
mutations were made available online. One of the studies conducted at Arizona State University discovered a huge base pair deletion in SARS-CoV-2 isolated from the sample of a patient in Temp.\textsuperscript{25} The other article, which was a preprint publication from the Los Alamos National Laboratory, tracked mutations throughout the outbreak and hypothesised that one of the strains of SARS-CoV-2 is more infectious than the first Wuhan strain.\textsuperscript{26} The study by Holland et al.\textsuperscript{25} revealed three full-length SARS-CoV-2 genomes from series of samples collected. The investigators found that one of the three genomes that they named AZASU2923 had an 81 base pair deletion in a gene called ORF7a.\textsuperscript{26} The major function of this ORF7a gene is to synthesise an accessory protein, which helps SARS-CoV-2 in infecting, replicating, and spreading inside the human host.\textsuperscript{26} The accessory protein is believed to assist SARS-CoV-2 in evading the host immune system and kill the infected cell once viral replication is complete.\textsuperscript{26}

In another study by van Dorp et al.,\textsuperscript{27} genome sequencing of SARS-CoV-2 isolated from more than 7500 patients of COVID-19 was undertaken. The study identified about 200 recurrent genetic mutations in SARS-CoV-2. This highlights how SARS-CoV-2 might have been adapting and evolving in humans.\textsuperscript{27} Scientists have identified that a large proportion of the global genetic diversity of SARS-CoV-2 can be found in the countries hardest-hit by COVID-19, suggesting extensive global transmission of SARS-CoV-2 early during the epidemic and the absence of single first patient in most countries and territories.

For instance, the genomic sequences of the original isolates from China are significantly related to those circulating in the U.S. and Europe. However, SARS-CoV-2 has been undergoing several mutations, which has made the world wonder whether these mutations could lead to a more severe and deadlier COVID-19.\textsuperscript{28} Perhaps, the SARS-CoV-2 strains circulating in sub-Saharan Africa might be those that initially circulated during the early phase of the COVID-19 pandemic, which have probably undergone little or no mutation. For instance, the first SARS-CoV-2 sequence from Africa revealed a phylogenetic relation to early isolates from Wuhan.\textsuperscript{29} The S-type strains of SARS-CoV-2 were the first circulating strains and were reported to be less virulent.\textsuperscript{30} Hence, there is a need for more stringent quarantine measures for people with recent international travel history in the last 14 days to areas of low incidence and case fatality rates.

**Implications of SARS-CoV-2 genetic mutations on COVID-19 biomedical interventions**

Monitoring the genetic diversity, dynamics, and mutations of SARS-CoV-2 are very important in the development of effective antivirals and vaccines that could halt the replication and spread of the virus. Based on the available genome sequence data, it appears that the rate of mutation in SARS-CoV-2 is significantly lower than that reported during the SARS outbreak.\textsuperscript{31}

One of the easiest ways of treating SARS-CoV-2 infections during the pandemic could be through the use of plasma derived from convalescent patients with COVID-19.\textsuperscript{32} Polyclonal neutralization antibodies (Nabs) could be harvested from convalescent patients and effectively used in the treatment of newly infected patients.\textsuperscript{33} The RBD of SARS-CoV-2 S protein has been considered the most important target for the development of Nabs. This immuno-therapeutic agent blocks the binding and fusion of SARS-CoV-2 to cells/tissues expressing ACE2.\textsuperscript{33} A major concern in the use of Nabs in the immunotherapy of patients with COVID-19 is the emergence and expansion of multiple mutations in the RBD of SARS-CoV-2 S protein. There are fears that patients carrying a mutant S protein might not respond to Nabs from a donor with a different S protein phenotype. Although SARS-CoV Nabs are likely to be beneficial for an infected individual, these antibodies could potentially trigger immunopathogenic processes in patients with COVID-19 with dissimilar viral genome content or enhanced infection.\textsuperscript{34} Antibodies to SARS-CoV-2 with different epitopes expressed by mutants of RBD generally fail to cross-neutralise all strains of SARS-CoV-2 and thus becomes suboptimal in treatment.\textsuperscript{34}

Due to the impact of COVID-19 on the global economy and the need to scale up public health laboratory tests for COVID-19, there is an urgency to consider the evaluation and validation of SARS-CoV-2 infection using enzyme linked immunosorbent assay (ELISA) and lateral flow immunochromatography rapid diagnostic test (RDT). Even though not all the available antigen- and antibody (IgA, IgM, and IgG)-based serological tests have been validated by the World Health Organization (WHO), it has been suggested that serological assays could assist in the analysis of an ongoing SARS-CoV-2 outbreak and retrospective evaluation of the incidence rate of an outbreak, and could support diagnosis of COVID-19 when RT-PCR results are negative.\textsuperscript{35}

In addition, RDTs for both IgM and IgG antibodies will undoubtedly play an important role in the detection of asymptomatic cases and in determining the immunity of health care workers as the outbreak progresses.\textsuperscript{36} However, one of the major concerns with serological tests is the possibility of cross-reaction with other SARS-CoVs, which share ~76% nucleotide homology with SARS-CoV-2.\textsuperscript{37} Indeed, cross-reactive antibodies are frequently detected in S protein ELISA.\textsuperscript{38} Antibodies to SARS-CoV-2 with different epitopes expressed by mutant proteins (either S or N) may reduce the positive predictive value of antibody-based anti-SARS-CoV-2 assays.

In a study that characterised eight mutation loci on the SARS-CoV-2 genome, researchers found that five loci with mutations had predominantly occurred in Europe, whereas the remaining three were exclusively present in North America (Table 2).\textsuperscript{39} They also reported a silent mutation in the RdRp gene circulating in England in early February 2020 and different mutations in RdRp gene that gave rise to variations in RdRp enzyme in Lombardy.\textsuperscript{39}

The findings of Pachetti et al.\textsuperscript{39} suggest that the SARS-CoV-2 that evolved in European, North American, and Asian strains have coexisted, with each having characteristic mutation pattern. Indeed, the impact of RdRp mutation to the evolution of SARS-CoV-2 needs to be investigated. There are several antivirals that target SARS-CoV-2 RdRp. Consequently, it is important to investigate and characterise SARS-CoV-2 RdRp mutations in order to detect possible drug-resistant SARS-CoV-2 traits. In addition, evaluation of the correlation of the presence of some mutations of RdRp...
with COVID-19 mortality rates will be clinically useful. In the study, the investigators found RdRp mutation at position 14,408 of SARS-CoV-2 genome circulating in Europe and associated with a higher number of point mutations compared to viral genomes from Asia. Hence, clinicians need to be very careful in the use of antiviral that target SARS-CoV-2 RdRp enzyme.

**Conclusion**

Investigations and surveillance of genetic diversity and mutation in SARS-CoV-2 may be valuable for scientists and clinicians. These may also help in better understanding the ways in which the genetic diversity and mutation affect the transmission and pathogenesis of SARS-CoV-2. Given the critical importance of SARS-CoV-2 mutations in COVID-19 pathogenicity, and in development of sero-diagnostics, antivirals, and vaccines, it is recommended that SARS-CoV-2 molecular surveillance efforts be sustained in order to facilitate the prompt identification of new mutants and their impact on ongoing biomedical interventions and COVID-19 control measures.

**Source of funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

| Citation          | Country | Experimental design                          | Mutations                                      | Key Findings                                                                 |
|-------------------|---------|----------------------------------------------|-----------------------------------------------|-------------------------------------------------------------------------------|
| Tang et al.13     | China   | Population genetic analyses of 103 SARS-CoV-2 genomes | Receptor-binding domain of the S protein       | L and S lineages discovered. L lineage was more prevalent than the S lineage. L lineage was evolutionarily aggressive and contagious compared to S lineage |
| Angeletti et al.12 | Italy   | Fast-unconstrained Bayesian approximation and Homology modelling | NSP2 and NSP3                                  | a. NSP2 mutation could explain why SARS-CoV-2 is more contagious than SARS-CoV-1  
 b. NSP3 mutation could explain the difference in pathogenicity between SARS-CoV-2 and SARS-CoV-1 |
| Yao et al.18      | China   | Functional characterisation of 11 patient-derived viral isolates | Intrapersonal variation and 6 different mutations in S protein | S protein mutation capable of substantially changing its pathogenicity |
| Xi et al.19       | China   | Phylogenetic analysis and heat mapping of 788 confirmed patients with COVID-19 | Furin cleavage site mutation on S protein     | FCS mutation may represent an important SARS-CoV-2 evolution site |
| Holland et al.26  | USA     | Genomic characterisation of a 27 amino acid in frame deletion in accessory protein ORF7a | An 81-nucleotide deletion in SARS-CoV-2 ORF7a | Phylogenetically distinct mutants that indicate independent transmissions pattern |
| Korber et al.26   | USA     | Phylogenetic analysis of S protein            | D614G mutation in S protein                    | Significant implications for SARS-CoV-2 transmission, pathogenesis, and immune interventions |
| van Dorp et al.27 | UK      | Curation of dataset of 7666 public genome and genomic diversity analysis | Nsp6, Nsp11, Nsp13, Spike protein              | Possible ongoing adaptation events of SARS-CoV-2 |
| Pachetti et al.39 | Italy   | 220 genomic sequences analysis from database derived from patients with COVID-19 | 8 novel recurrent mutations of SARS-CoV-2 RdRp | a. Findings suggest SARS-CoV-2 evaluation and co-existence in European, North American, and Asian strains  
 b. RdRp mutation could be involved in antiviral drug-resistance |
| Happi et al.40    | Nigeria | Genome annotation and Mutation Analysis       | D614G in S protein                              | D614G mutation in S protein could be associated with higher transmission and pathogenicity and evasion of immune interventions |
Conflict of interest

The authors have no conflict of interest to declare.

Ethical approval

Not applicable.

Authors contributions

INA and OAA conceived and designed the study, and conducted the preliminary review of articles. INA, AUE, and AIO provided research scope, and collected and organised the extracted data. INA, AUE, DOA, and BSO analysed and interpreted the data. INA, OAA, AUE, DAO, and AIO wrote the initial and final drafts of the article, and provided logistic support. All authors have critically reviewed and approved the final draft and are responsible for the content and similarity index of the manuscript.

Acknowledgment

Authors greatly appreciate the technical inputs provided by Peter Elisha Gamba of the WHO National Polio Virus Laboratory, University of Maiduguri Teaching Hospital, Nigeria.

References

1. Worldometers.info. Situation update worldwide, as of 29th May, Delaware, USA: Dove; 2020. Retrieved from: https://www.worldometers.info/coronavirus/#countries. Last accessed 29th May, 2020.

2. Hao P, Zhong W, Song S, Fan S, Li X. Is SARS-CoV-2 originated from laboratory? A rebuttal to the claim of formation via laboratory recombination. Emerg Microb Infect 2020; 9(1): 545–547.

3. Mousavi-Sedigh L, Ghasemi S. Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect 2020. https://doi.org/10.1016/j.jmii.2020.03.022.

4. Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Med Res 2020; 7(11). https://doi.org/10.1186/s40779-020-00240-0.

5. Liu C, Zhou Q, Li Y, Garner L, Watkins S, Carter L, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020; 6: 315–331.

6. Yuan Y, Cao D, Zhang Y, Ma J, Qi J, Wang Q, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun 2018; 8: 15092.

7. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. JPharm Anal 2020; 1–17.

8. Wrapp D, Wag N, Corbett K, Goldsmith J, Hsieh C, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367: 1260–1263.

9. Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol 2018; 16(8):e3000003. https://doi.org/10.1371/journal.pbio.3000003.

10. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol 2020. https://doi.org/10.1128/JVI.00127-20. Epub ahead of print.

11. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020. https://doi.org/10.1016/j.chom.2020.02.001. Epub ahead of print.

12. AngelettiS, Benvenuto D, Bianchi M, Giovannetti M, Pascarella S, Ciccozzi M. COVID-19: the role of the nsp2 and nsp3 in its pathogenesis. J Med Virol 2020. https://doi.org/10.1002/jmv.25719.

13. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2. Nat Sci Rev 2020. https://doi.org/10.1093/nsr/nwa036.

14. Wang C, Li W, Drabek D, Okba NMA, Haperen R, Osterhaus ADME, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. BioRxiv 2020; 03.11.987958.

15. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterol 2020; 158(6): 1831–1833.e3. https://doi.org/10.1053/j.gastro.2020.02.055.

16. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV. BioRxiv 2020; 01.26.919985.

17. Lv L, Li G, Chen J, Liang X, Li Y. Comparative genomic analysis revealed specific mutation pattern between human coronavirus SARS-CoV-2 and Bat-SARSr-CoV RaTG13. BioRxiv 2020; 02.27.969006.

18. Yao H, Lu X, Chen Q, Xu K, Chen Y, Cheng L, et al. Patient-derived mutations impact pathogenicity of SARS-CoV-2; 2020. https://doi.org/10.1101/2020.04.14.20061060.

19. Xi J, Xu K, Jiang P, Liao J, Hao S, Yao H, et al. Virus strain of a mild COVID-19 patient in Hangzhou represents a new trend in SARS-CoV-2 evolution related to Furin cleavage site; 2020. https://doi.org/10.1101/2020.03.12.20033944.

20. Nanshan CMZ, DongX, Qu J, Gong F, Han Y, Qiu Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 7: S0140-6736(20).

21. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. New England, London: Lancet; 2020.

22. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series; 2020. 2020m606.

23. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention [published online ahead of print, 2020 Feb 24]. JAMA 2020. https://doi.org/10.1001/jama.2020.2648.

24. Zou L, Ruan F, Huang M, Liang L, Huang H, Zong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382(12): 1177–1179.

25. Holland LA, Kaelin EA, Maqsood R, Estifanos B, Wu Li, Abfalterer W, et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. Med Res 2020; 2020m606.

26. Korber B, Fischer WM, Gnanakaran G, Yoon H, Theiler J, Osterhaus ADME, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. BioRxiv 2020; 03.11.987958.

27. van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, et al. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol 2020. https://doi.org/10.1016/j.meegen.2020.104351.

28. Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol 2020; (81): 104260. https://doi.org/10.1016/j.meegen.2020.104260.
29. Ihekweazu C, Happi C, Omilabu S, Salako BL, Abayomi A, Olaniyi P. First African SARS-CoV-2 genome sequence from Nigerian COVID-19 case; 2020. http://virological.org/t/first-african-sars-cov-2-genome-sequence-from-nigerian-covid-19-case/421. Last accessed 8th April, 2020.

30. Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. *Military Med Res* 2020; 7(11). https://doi.org/10.1186/s40779-020-00240-0.

31. Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. *Emerg Microb Infect* 2020; 9: 275–277.

32. Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. *F1000Research* 2020; 9: 72.

33. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020. https://doi.org/10.1038/s41586-020-2012-2.

34. Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. *Trend Immunol* 2020; 41(5): 5355–5359.

35. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases; 2 March 2020.

36. Tang Y, Schmitz JE, Persing DH, Stratton CW. The laboratory diagnosis of COVID-19 infection: current issues and challenges. *J Clin Microbiol* 2020. https://doi.org/10.1128/JCM.00512-20.

37. Xiao S, Wu Y, Liu H. Evolving status of the 2019 novel coronavirus infection: proposal of conventional serologic assays for disease diagnosis and infection monitoring. *J Med Virol* 2020; 92: 464–467. https://doi.org/10.1002/jmv.25702.

38. Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses. *J Med Virol* 2020. https://doi.org/10.1002/jmv.25715.

39. Pachetti M, Marini B, Benedetti F. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. *J Transl Med* 2020; 18: 1–9. https://doi.org/10.1186/s12967-020-02344-6.

40. Happi C, Ihekweazu C, Oluniyi PE, Olawoye I. SARS-CoV-2 genomes from Nigeria reveal community transmission, multiple virus lineages and spike protein mutation associated with higher transmission and pathogenicity. *Virological* 2020. http://virological.org/t/sars-cov-2-genomes-from-nigeria-reveal-community-transmission-multiple-virus-lineages-and-spike-protein-mutation-associated-with-higher-transmission-and-pathogenicity/494. Last accessed on 2nd June, 2020.